ArticleFrontiers in oncology2026
Fecal hemoglobin concentration as a risk stratification tool for advanced colorectal neoplasm in a community-based screening program.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Compared with traditional binary classification, the quantitative fecal immunochemical test (qFIT) provides detailed fecal hemoglobin (f-Hb) concentrations, which facilitate more refined risk stratification for advanced colorectal neoplasm; however, this approach remains underexplore. Methods: Based on the Shanghai colorectal cancer (CRC) screening program, 7,097 residents were enrolled. Participants who completed both qFIT and colonoscopy were included in the analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) derived from logistic regression models were used to evaluate the association between f-Hb concentration and the risk of advanced neoplasm. Subgroup analyses by age and sex were conducted for further risk stratification. Results: The median f-Hb concentration was significantly higher in participants with advanced neoplasm (71 ng/mL; interquartile range[IQR]: 20-412 ng/mL) compared with those without neoplasm (19 ng/mL; IQR: 11-41.5 ng/mL) (P<0.001). The proportion of advanced neoplasm increased with rising f-Hb concentration. Logistic regression analysis revealed that, compared with participants with f-Hb <50 ng/mL, 2.91-fold, 3.92-fold, and 24.21-fold increased risks of advanced neoplasm were observed for those with f-Hb of 50-99 ng/mL, 100-799 ng/mL, and ≥800 ng/mL, respectively. According to sex, age, and f-Hb concentration, 16 categories were identified. Risk stratification was based on ORs as follows: reference, normal risk; 1 to <3, low risk; 3 to <10, moderate risk; and ≥10, high risk. Using this criterion, 674 (71.25%), 138 (14.59%), 103 (10.89%), and 31 (3.28%) participants were classified into the normal-, low-, moderate-, and high-risk groups, respectively. Conclusions: F-Hb concentration is predictive of the severity of colorectal neoplasm and may be used for risk stratification of advanced neoplasm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.